Diabetes

Your daily dose of the clinical news you may have missed.

Novo Nordisk aims to revolutionize diabetes care with its resubmission for insulin icodec, a potential first once-weekly basal insulin for type 2 diabetes therapy in adults.

In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.

EASD 2025: The risk of developing the 4 primary subtypes of T2D was increased by as much as 3-fold and was not dependent on duration of smoking behavior.

Your daily dose of the clinical news you may have missed.

Nor does receiving a diabetes diagnosis guarantee optimal management as just one-fifth of people treated for the disease reached glycemic control in 2023.

Your daily dose of the clinical news you may have missed.

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

The combination of the Dexcom Stelo glucose biosensor with an AI platform provides real-time data on how food, exercise, stress, and sleep affect the body.

Your daily dose of the clinical news you may have missed.

A Cleveland Clinic trial revealed that AI-driven precision treatment significantly reduced HbA1c and body weight, often eliminating need for medications other than metformin.

GLP-1 use among adults with diabetes peaked among those aged 50 to 64 years, was highest among Hispanic adults, and was more likely among those taking other antihyperglycemic agents.

Your daily dose of the clinical news you may have missed.

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.

Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.

Dr Khanna discusses how PCPs can use patient relationships to tailor lifestyle advice and manage obesity-related cardiometabolic disease.

Dr Khanna urges early screening for cardiometabolic risk in patients with obesity and highlights the role of primary care in prevention and education.

Without a shift in the approach to disease prevention and management in the US, the health system won't be able to handle the burden of our morbidity, says Richard Rosenfeld, MD, MPH, MBA.

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Richard Rosenfeld, MD, MPH, MBA, led the development of lifestyle medicine guidelines to treat or even reverse prediabetes and type 2 diabetes.

Lead author for the American College of Lifestyle Medicine's new clinical practice guideline discusses the broad endorsement for the recommendations across participating groups.